- Home
- BRKR vs LEGN Comparison
BRKR vs LEGN Comparison
Compare BRKR & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRKR
- LEGN
- Stock Information
- Founded
- BRKR 1960
- LEGN 2014
- Country
- BRKR United States
- LEGN United States
- Employees
- BRKR N/A
- LEGN N/A
- Industry
- BRKR Biotechnology: Laboratory Analytical Instruments
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- BRKR Industrials
- LEGN Health Care
- Exchange
- BRKR Nasdaq
- LEGN Nasdaq
- Market Cap
- BRKR 5.3B
- LEGN 6.3B
- IPO Year
- BRKR 2000
- LEGN 2020
- Fundamental
- Price
- BRKR $38.94
- LEGN $32.40
- Analyst Decision
- BRKR Buy
- LEGN Strong Buy
- Analyst Count
- BRKR 10
- LEGN 12
- Target Price
- BRKR $49.67
- LEGN $70.82
- AVG Volume (30 Days)
- BRKR 3.1M
- LEGN 1.4M
- Earning Date
- BRKR 11-03-2025
- LEGN 11-12-2025
- Dividend Yield
- BRKR 0.51%
- LEGN N/A
- EPS Growth
- BRKR N/A
- LEGN N/A
- EPS
- BRKR 0.52
- LEGN N/A
- Revenue
- BRKR $3,442,800,000.00
- LEGN $796,838,000.00
- Revenue This Year
- BRKR $4.30
- LEGN $68.68
- Revenue Next Year
- BRKR $1.51
- LEGN $48.49
- P/E Ratio
- BRKR $74.77
- LEGN N/A
- Revenue Growth
- BRKR 10.36
- LEGN 74.75
- 52 Week Low
- BRKR $28.53
- LEGN $27.34
- 52 Week High
- BRKR $64.64
- LEGN $47.79
- Technical
- Relative Strength Index (RSI)
- BRKR 58.94
- LEGN 47.15
- Support Level
- BRKR $38.60
- LEGN $31.60
- Resistance Level
- BRKR $41.08
- LEGN $32.71
- Average True Range (ATR)
- BRKR 1.68
- LEGN 1.30
- MACD
- BRKR -0.12
- LEGN 0.11
- Stochastic Oscillator
- BRKR 61.23
- LEGN 28.78
About BRKR Bruker Corporation
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.